"Pharmacogenetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
| Descriptor ID |
D010597
|
| MeSH Number(s) |
H01.158.273.343.750 H01.158.703.052 H02.628.479
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenetics".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenetics".
This graph shows the total number of publications written about "Pharmacogenetics" by people in this website by year, and whether "Pharmacogenetics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 3 | 3 |
| 2005 | 4 | 4 | 8 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 2 | 2 |
| 2009 | 2 | 5 | 7 |
| 2010 | 3 | 6 | 9 |
| 2011 | 1 | 6 | 7 |
| 2012 | 1 | 7 | 8 |
| 2013 | 1 | 4 | 5 |
| 2014 | 2 | 8 | 10 |
| 2015 | 3 | 5 | 8 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 5 | 6 |
| 2018 | 2 | 2 | 4 |
| 2019 | 3 | 3 | 6 |
| 2020 | 4 | 5 | 9 |
| 2021 | 2 | 1 | 3 |
| 2022 | 5 | 1 | 6 |
| 2023 | 4 | 2 | 6 |
| 2024 | 3 | 2 | 5 |
| 2025 | 5 | 0 | 5 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenetics" by people in Profiles.
-
Genetics and Genomics in Sickle Cell Disease in Africa. Am J Hematol. 2026 04; 101 Suppl 1:47-55.
-
CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use. Expert Rev Clin Pharmacol. 2026 Jan-Feb; 19(2):133-150.
-
Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clin Pharmacol Ther. 2026 Jan; 119(1):109-119.
-
Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities. Genet Med. 2025 Oct; 27(10):101529.
-
Clinical impact of pharmacogenetic risk variants in a large chinese cohort. Nat Commun. 2025 Jul 09; 16(1):6344.
-
Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic. Pharmacogenomics. 2024; 25(16-18):637-645.
-
Pharmacogenetic and microRNA mechanisms of beta blocker use on bone. J Bone Miner Res. 2025 Feb 02; 40(2):231-240.
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 01; 45(1):4-11.
-
Providers'?use of pharmacogenetic testing to inform opioid prescribing among veterans. Pharmacogenomics. 2024; 25(12-13):495-501.
-
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation. Pharmacogenet Genomics. 2025 01 01; 35(1):1-11.